ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-OR05

Machine Learning-Guided Novel Subphenotypes of Sepsis-Associated Persistent AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Oh, Wonsuk, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Kittrell, Hannah, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Kohli-Seth, Roopa D., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Nadkarni, Girish N., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Sakhuja, Ankit, West Virginia University, Morgantown, West Virginia, United States

Sepsis associated acute kidney injury (SA-AKI) is common and is associated with high mortality. AKI lasting 48 hours or longer, known as persistent AKI (pAKI), has much worse outcomes. SA-AKI is a heterogenous disease, however, it is unknown whether such heterogeneity exists in SA-pAKI. We aimed to identify subphenotypes (SP) of SA-pAKI using routinely collected data in electronic medical records.


We conducted a retrospective study using MIMIC IV database. We defined AKI and pAKI using both creatinine and urine output based KDIGO criteria. We identified adult patients (≥18y) with sepsis who developed SA-AKI within 48h and SA-pAKI within 96h of ICU admission. We used available features for demographics, comorbidities, SOFA score, vital signs, labs, fluid balance & vasopressors to identify SPs. We used factor analysis of mixed data for dimensionality reduction followed by k-means clustering to identify SPs. Outcomes were 30-day in-hospital mortality and 30-day AKI recovery while adjusting for competing risk of mortality.


Among 6,681 patients with SA-pAKI, we identified 4 distinct SPs. Each SP demonstrated distinct characteristics and outcomes (Fig 1a & b). SP1 (n=1,137) included patients with severe AKI, low systolic BP, high INR, and WBC counts. It had highest mortality(47%) and low AKI recovery(37%). SP 2 (n=1,231) had moderate to severe AKI but low vasopressor requirements. It had low mortality (19%) but also low rates of AKI recovery (32%). SP3 (n=1315) included patients with high comorbidity burden but low disease acuity. Their mortality was between that of first two SPs and had high rates of AKI recovery (54%). SP4 (n=1,678) included patients with mild to moderate AKI and low disease acuity. They had highest rates of AKI recovery (56%) and lowest mortality (13%).


We identified 4 distinct SPs of SA-pAKI with differing patient characteristics and outcomes. Early recognition of these SPs will allow for personalized management strategies.


  • NIDDK Support